Search for: "KV Pharmaceuticals"
Results 41 - 60
of 92
Sorted by Relevance
|
Sort by Date
31 Jul 2008, 9:44 pm
What do we know about KV Pharmaceutical? [read post]
25 Mar 2009, 12:17 pm
As we have reported previously, here, during the past year there have been other cGMP violations leading to generic drug recalls by Actavis, ETHEX / KV Pharmaceutical, and Sandoz / Novartis. [read post]
27 Jan 2011, 5:00 am
KV Pharmaceutical Co., ___ F.3d ___, 2011 WL 148730 (8th Cir. [read post]
10 May 2011, 7:25 am
When KV announced it would charge about hundred times what patients were paying at compounding pharmacies, a firestorm of criticism ensued, and the pharmaceutical company has backpedaled on its pricing. [read post]
5 Nov 2006, 8:29 pm
KV Pharmaceutical Uniretic--Schwarz Pharma v. [read post]
3 Apr 2011, 6:59 am
As the FDA states on its website: FDA understands that the manufacturer of Makena, KV Pharmaceuticals, has sent letters to pharmacists indicating that FDA will no longer exercise enforcement discretion with regard to compounded versions of Makena. [read post]
22 Sep 2011, 9:59 am
Oral argument argued before the Eighth Circuit U.S. [read post]
3 Jul 2013, 5:48 am
KV Pharmaceutical). [read post]
9 Jul 2012, 2:00 am
We also discuss a First Circuit decision affirming the dismissal of a securities fraud action against Textron; a Second Circuit ruling addressing the standard for pleading a failure to disclose “known uncertainties” under Item 303 of Regulation S-K; and an Eighth Circuit decision reversing the dismissal of a securities fraud action against KV Pharmaceutical Company. [read post]
23 Jul 2007, 4:04 pm
KV Pharmaceutical Co.), No. 06-1254 (Fed. [read post]
9 Jul 2012, 2:00 am
We also discuss a First Circuit decision affirming the dismissal of a securities fraud action against Textron; a Second Circuit ruling addressing the standard for pleading a failure to disclose “known uncertainties” under Item 303 of Regulation S-K; and an Eighth Circuit decision reversing the dismissal of a securities fraud action against KV Pharmaceutical Company. [read post]
2 Feb 2009, 9:51 am
This January 2008 press release from KV Pharmaceutical, the parent company of ETHEX, includes a list of the more than 60 generic drugs being recalled by ETHEX. [read post]
25 Jul 2007, 8:10 pm
KV Pharmaceutical, Andrx, and Eon Labs have all filed ANDAs for generic Toprol-XL and are defendants in the litigation. [read post]
11 Jan 2010, 6:00 am
KV Pharmaceutical Co., No. 4:09CV00588SNLJ, slip op. [read post]
27 Dec 2011, 9:56 am
Janssen Pharmaceuticals, Inc., 951 N.E.2d 1238 (Ill. [read post]
9 Dec 2011, 12:52 pm
” The government “claimed that Ethex Corp., a now-defunct unit of KV Pharmaceutical, misrepresented the regulatory status of Nitroglycerin ER and Hyoscyamine Sulfate ER, according to the statement. [read post]
4 Aug 2010, 12:21 am
Mylan Pharmaceuticals Inc. [read post]
1 Dec 2009, 9:39 am
KV Pharmaceutical Corp., 2008 WL 2937415 (D.N.J. 2008). [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging novelty:… [read post]
12 Dec 2008, 7:00 am
EU: European Commission preliminary report on its inquiry into competition in the pharmaceutical sector (Spicy IP) (Intellectual Property Watch) (Patent Baristas) EU: Enlarged Board of the EPO denies WARF’s patent application directed to human embryonic stem cells (Patent Docs) US: Patent Office assault on pharma industry (PLI) US: Proponent of gene patent ban Rep Xavier Becerra to leave Congress (Patent Docs) US: Merck & Co starts generic arm BioVentures to copy biologic… [read post]
